UTILIZING PREDICTIVE BIOMARKERS TO IMPROVE TREATMENT OUTCOMES IN PATIENTS WITH METASTATIC COLORECTAL CANCER (mCRC): RESULTS WITH CETUXIMAB PLUS FOLFIRI IN THE CRYSTAL TRIAL

被引：0
|
作者：
Rougier, P. [1 ]
Janciauskiene, R. [2 ]
Paramonov, V [3 ]
Shparyk, Y. [4 ]
Gustavsson, B. [5 ]
Wagnerova, M. [6 ]
Gorbunova, V [7 ]
Utracka-Hutka, B. [8 ]
Celik, I [9 ]
Van Cutsem, E. [10 ]
机构：
[1] Hop Ambroise Pare, Boulogne, France
[2] Kauno Med Univ Klin, Kaunas, Lithuania
[3] Cherkassy Oblasnoy Onkodispanser, Charkassy, Ukraine
[4] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[5] Sahlgrens Univ Hosp, Gothenburg, Sweden
[6] Vychodoslovensky Onkol Ustav, Kosice, Slovakia
[7] RAMN, NN Blokhin Russian Canc Res Ctr, Moscow, Russia
[8] MSC Mem Canc Ctr, Gliwice, Poland
[9] Merck KGaA, Darmstadt, Germany
[10] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：15 / 15
页数：1
相关论文
共 50 条
  • [41] Cetuximab plus FOLFIRI as first-line treatment for metastatic colorectal CA.
    Rougier, P
    Raoul, JL
    Van Laethem, JL
    Peeters, M
    Husseini, F
    Brezault, C
    Cals, L
    Vedovato, JC
    Mueser, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 248S - 248S
  • [42] Cetuximab plus FOLFIRI for irinotecan-refractory metastatic colorectal cancer: A retrospective study
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Ryu, Min-Hee
    Chang, Heung Moon
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    ANNALS OF ONCOLOGY, 2006, 17 : 131 - 131
  • [43] EFFECTIVENESS AND SAFETY OF FIRST-LINE BEVACIZUMAB PLUS FOLFIRI IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC)
    Pinto, Ana Catarina
    Teixeira, Margarida
    Bonito, Nuno
    Jacinto, Paula
    Ribeiro, Joao
    Gervasio, Helena
    ANNALS OF ONCOLOGY, 2011, 22 : v98 - v98
  • [44] Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI 1 cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
    Cardone, C.
    Paul, M. C.
    Moreno-Viedma, V.
    Martini, G.
    Vitiello, P. P.
    Ciardiello, D.
    Sforza, V.
    Troiani, T.
    Napolitano, S.
    Vitale, P.
    Zanaletti, N.
    Rachiglio, A. M.
    Rizzi, D.
    Maiello, E.
    Normanno, N.
    Sibilia, M.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [45] Eph A2 expression is a predictive biomarker of poorer activity and efficacy of FOLFIRI 1 cetuximab in RAS WT metastatic colorectal cancer (mCRC) patients (pts) in the CAPRI GOIM trial
    Cardone, C.
    Paul, M. C.
    Moreno-Viedma, V.
    Martini, G.
    Vitiello, P. P.
    Ciardiello, D.
    Sforza, V.
    Troiani, T.
    Napolitano, S.
    Vitale, P.
    Zanaletti, N.
    Rachiglio, A. M.
    Rizzi, D.
    Maiello, E.
    Normanno, N.
    Sibilia, M.
    Ciardiello, F.
    Martinelli, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Treatment patterns and outcomes in metastatic colorectal cancer (mCRC).
    Cartwright, Thomas H.
    Wen, Lonnie Kent
    Harrell, Robyn K.
    Fox, Patricia S.
    Espirito, Janet L.
    Wang, Ed
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [47] Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).
    Tatli, Ali Murat
    Coskun, Hasan Senol
    Uysal, Mukremin
    Goksu, Sema Sezgin
    Arslan, Deniz
    Gunduz, Seyda
    Ozdogan, Mustafa
    Bozcuk, Hakan Sat
    Savas, Burhan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab plus FOLFIRI
    Karthaus, M.
    Hofheinz, R.
    Mineur, L.
    Letocha, H.
    Greil, R.
    Thaler, J.
    Fernebro, E.
    Zhang, Y.
    Oliner, K. S.
    Demonty, G.
    Koehne, C. H.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S375 - S376
  • [49] Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
    Hamaguchi, Tetsuya
    Denda, Tadamichi
    Kudo, Toshihiro
    Sugimoto, Naotoshi
    Ura, Takashi
    Yamazaki, Kentaro
    Fujii, Hirofumi
    Kajiwara, Takeshi
    Nakajima, Takako Eguchi
    Takahashi, Shin
    Otsu, Satoshi
    Komatsu, Yoshito
    Nagashima, Fumio
    Moriwaki, Toshikazu
    Esaki, Taito
    Sato, Takeo
    Itabashi, Michio
    Oki, Eiji
    Sasaki, Toru
    Chiron, Marielle
    Yoshino, Takayuki
    CANCER SCIENCE, 2019, 110 (11) : 3565 - 3572
  • [50] A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer
    Santoro, A.
    Comandone, A.
    Rimassa, L.
    Granetti, C.
    Lorusso, V.
    Oliva, C.
    Ronzoni, M.
    Siena, S.
    Zuradelli, M.
    Mari, E.
    Pressiani, T.
    Carnaghi, C.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1888 - 1893
12345